La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Biote a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Biote..

Biote (NASDAQ:BTMD) Azioni, Catena delle Opzioni

Biote

Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations.

Biote Corp

HC Wainwright &amp; Co. analyst Robert Burns reiterates Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) with a Buy and maintains $22 price target.

News

Price Target

Reiteration

Analyst Ratings

YMAB

HC Wainwright & Co. Reiterates Buy on Y-mAbs Therapeutics, Maintains $22 Price Target

Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) with a Overweight and lowers the price target from $20 to $12.

CABA

Wells Fargo Maintains Overweight on Cabaletta Bio, Lowers Price Target to $12

The recent U.S. presidential election results, including a Republican sweep, have raised questions about the future of renewable energy under President-elect Donald Trump&#8217;s leadership.
Morgan Stanley&#8217;s report evaluates the economic impact on renewables under various policy scenarios and its effects on earnings.
The analyst has adjusted its view on the clean tech industry to &#8220;In-Line&#8221; from &#8220;Attractive.&#8221;
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41880110/solar-renewables-stocks-crash-after-trump-win-should-you-buy-now-at-cheap-valuations" rel="noreferrer noopener">Solar, Renewables Stocks Crash After Trump Win: Should You Buy Now At Cheap Valuations?</a>
While long-term demand for renewables is likely stronger than current market perceptions, near-term growth prospects have become less clear due to new uncertainties.
It&#8217;s important to remember that these new uncertainties add to the already difficult environment facing the clean energy sector, dealing with issues such as permitting and interconnection delays, funding challenges, and intense competition that have hurt profitability.
Uncertainty about the Inflation Reduction Act (IRA), tariffs, and interest rates has significantly impacted clean fuel valuations.
Morgan Stanley writes that clear guidance on the IRA is essential for clean tech valuations to rebound. However, this may take time since it will likely be linked to discussions about the Tax Cuts and Job Act&nbsp;(TCJA), which is set to expire at the end of 2025.
Morgan Stanley recommends investing in stocks with high-quality and durable growth/ margins, with a clear catalyst path and/or strong balance sheet to weather any near-term volatility in growth and/or profitability.
<ul>
<li>The analyst maintains an Overweight rating on GE Vernova Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>), First Solar Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>), and Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>).</li>
</ul>
However, the analyst has downgraded three cleantech stocks from Equal-weight to Underweight, including:
<ul>
<li>SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>): The analyst reduced the price target from $23 to $9, citing slower profitability due to decreased European demand and tough competition from cheaper Chinese manufacturers. As a result, the company is not expected to break even on <a href="https://www.benzinga.com/quote/SEDG/analyst-ratings" target="_blank" rel="noreferrer noopener">EBITDA until after 2026</a>. At last check Friday, the stock was trading 13.2% lower at $11.13.</li>
<li>Maxeon Solar Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAXN#NASDAQ">MAXN</a>): Morgan Stanley anticipates a slow recovery to profitability due to increasing competition in Europe&#8217;s utility-scale solar market, which will likely keep pushing prices down. The analyst maintains the <a href="https://www.benzinga.com/quote/MAXN/analyst-ratings" target="_blank" rel="noreferrer noopener">price target of $4</a>. Additionally, recent customer losses in the U.S. residential market could make maintaining market share and premium pricing harder. Stock is trading 10.08% lower at $10.08 at last check Friday.</li>
<li>TPI Composites, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPIC#NASDAQ">TPIC</a>): The analyst notes an uncertainty about how quickly the U.S. wind market will recover, mainly due to challenges in securing financing and recent issues with design and inspections as the industry shifts to larger blade sizes. Morgan Stanley has cut the <a href="https://www.benzinga.com/quote/TPIC/analyst-ratings" target="_blank" rel="noreferrer noopener">price target from $4 to $2</a>. Stock is down 8.82% at $2.16 at the last check Friday.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/42012689/life-insurance-firm-aegon-trades-higher-as-capital-ratios-remain-solid" target="_blank" rel="noreferrer noopener">Life Insurance Firm Aegon Trades Higher As Capital Ratios&#8217; Remain Solid&#8217;</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Government

Large Cap

Downgrades

Movers

Trading Ideas

General

FSLR

Maxeon Solar Technologies, Ltd. - Ordinary Shares

MAXN

SEDG

TPIC

Trump's Win, Economic Challenges Lead to Tougher Outlook for Renewable Energy Stocks: Morgan Stanley

Wells Fargo analyst Derek Archila maintains Kyverna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYTX#NASDAQ">KYTX</a>) with a Overweight and lowers the price target from $44 to $24.

KYTX

Wells Fargo Maintains Overweight on Kyverna Therapeutics, Lowers Price Target to $24

Wells Fargo analyst Roger Read maintains Coterra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) with a Overweight and raises the price target from $32 to $35.

CTRA

Wells Fargo Maintains Overweight on Coterra Energy, Raises Price Target to $35

Guggenheim analyst Michael Schmidt maintains Zentalis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZNTL#NASDAQ">ZNTL</a>) with a Buy and lowers the price target from $12 to $8.

ZNTL

Guggenheim Maintains Buy on Zentalis Pharma, Lowers Price Target to $8

Macro Economic Events

Economics

Federal Reserve

Fed's Goolsbee Says Everything Is Always On The Fed Policy Table; Inflation Numbers Have To Keep Improving; If Started To See Reversal On Inflation Progress, Would Have To Figure Out If It Is A Bump; Not A Lot Has Changed On That In Last Couple Weeks; Recent Inflation Has Been A Little Higher Than Target, If That Is Extended, It's Too High; There's A Lot Of Volatility On Inflation Data Series

Telsey Advisory Group analyst Dana Telsey maintains Tapestry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) with a Outperform and raises the price target from $58 to $67.

Telsey Advisory Group Maintains Outperform on Tapestry, Raises Price Target to $67

Guggenheim analyst Robert Drbul maintains Tapestry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) with a Buy and raises the price target from $60 to $70.

Guggenheim Maintains Buy on Tapestry, Raises Price Target to $70

Fed's Goolsbee Asked About A December Rate-Cut Pause, Says He Doesn't Like Tying Our Hands, Still More Data To Come; Markets React Immediately And In Most Extreme Terms; That's Not The Fed Timetable; Fed Needs To Focus On Longer Trends; We Are Going To Be Looking At Rate Cuts Along The Lines Of September Fed Policymaker Projections; Personally Comfortable With Not Charging Right Towards Neutral, Slow Down As We Approach It

On Thursday, Bluebird Bio Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) reported a third-quarter EPS loss of 31 cents, compared to a loss of 80 cents a year ago, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41967541/bluebird-bio-reports-third-quarter-2024-results-and-highlights-operational-progress-and-2024-guida" rel="noreferrer noopener">consensus loss of 36 cents</a>.
The gene therapy company reported sales of $10.6 million, down from $12.39 million, missing the consensus of $18.1 million.
The company&#8217;s cash, cash equivalents, and restricted cash balance were approximately&nbsp;$118.7 million, which is expected to provide a cash runway into the first quarter of 2025.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41290857/worries-mount-over-cancer-risks-in-bluebird-bios-gene-therapy" rel="noreferrer noopener">Worries Mount Over Cancer Risks in Bluebird Bio&#8217;s Gene Therapy</a>
The company anticipates quarterly cash flow break-even in the second half of 2025, assuming it scales to approximately 40 drug product deliveries per quarter and obtains additional cash resources to extend its runway.
JP Morgan downgraded Bluebird after the third-quarter results. The analyst notes a reduced cash runway to &#8220;into 1Q25&#8221; from &#8220;into 2Q25.&#8221;
JP Morgan highlights that Bluebird did achieve the milestone of its first Lyfgenia infusion during the quarter (and revenue recognition) and continues to increase the pace of patient starts (cell collections) across its portfolio but is doing so against a backdrop of continued negative gross margins.
<ul>
<li>57 patient starts completed to date in 2024 (35 Zynteglo, 17 Lyfgenia, 5 Skysona).</li>
<li>Seventeen additional starts are scheduled through the remainder of 2024.</li>
</ul>
&#8220;Altogether presenting few avenues to emerge from remaining a going concern,&#8221; the analyst says. JP Morgan has downgraded from <a href="https://www.benzinga.com/quote/BLUE/analyst-ratings" target="_blank" rel="noreferrer noopener">Neutral to Underweight</a>.
The analyst writes that the proxy vote did not gather enough support to approve a reverse stock split and increase the number of shares available for issuance. This outcome effectively eliminates equity financing as an option for raising capital.
In September, Bluebird bio implemented a restructuring to optimize its cost structure and enable quarterly cash flow break-even in the&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41008825/gene-therapy-focused-bluebird-bio-restructures-cuts-is-workforce-by-25-seeks-to-breakeven-next-ye" rel="noreferrer noopener">second half of 2025</a>.
Price Action: BLUE stock is down 11.2% at $0.32 at last check Friday.
Photo by Ground Picture on Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42012924/mullen-drives-into-government-sector-with-electric-bollinger-b4-trucks" target="_blank" rel="noreferrer noopener">Mullen Drives Into Government Sector With Electric Bollinger B4 Trucks</a></li>
</ul>

Biotech

Earnings

Equities

BLUE

JP Morgan Downgrades Gene Therapy Focused Bluebird Bio, Cites Limited Funding Options

Guggenheim analyst Michael Morris maintains Walt Disney (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) with a Buy and raises the price target from $110 to $130.

Guggenheim Maintains Buy on Walt Disney, Raises Price Target to $130

Telsey Advisory Group analyst Dana Telsey maintains Dillard's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDS#NYSE">DDS</a>) with a Market Perform and raises the price target from $380 to $450.

Telsey Advisory Group Maintains Market Perform on Dillard's, Raises Price Target to $450

General Motors Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) has reportedly laid off 1,000 employees as part of its plan to reduce costs by $2 billion by the end of 2024. This follows earlier layoffs in its software and services division and voluntary buyouts in 2023, which affected 5,000 employees according to <a href="https://www.wsj.com/business/autos/gm-cuts-another-1-000-jobs-as-ev-push-continues-21ed77c8?mod=hp_lead_pos11">The Wall Street Journal.</a>
The company cited the need to optimize operations and focus on priorities. Other automakers, including Ford Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) and Volkswagen Inc., are also cutting costs due to weak global markets and high EV development expenses.
GM continues to expand its EV lineup but expects these vehicles to remain unprofitable in 2025. Gas-powered trucks and SUVs remain the company's most profitable segment, driving <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41462946/general-motors-strong-q3-earnings-impress-analysts-highlights-turnaround-and-ev-pro">better-than-expected third-quarter </a>results last month.
What Else: Cruise, GM's autonomous vehicle division, also <a href="https://www.benzinga.com/tech/24/11/42002804/gms-autonomous-driving-unit-cruise-admits-to-falsifying-accident-report-to-nhtsa-agrees-to-pay-500k-fine">admitted to falsifying an accident</a> report to the National Highway Traffic Safety Administration. The report failed to disclose full details of an Oct. 2023 crash in San Francisco where a Cruise robotaxi dragged a pedestrian 20 feet after the individual was hit by another vehicle.
Cruise will pay a $500,000 fine, create a Safety Compliance Program and submit annual reports to avoid further penalties. The company halted U.S. operations after the incident but resumed manual driving in Phoenix, Houston and Dallas earlier this year. It plans to return to driverless operations by year-end, according to GM CEO Mary Barra.
GM Price Action: General Motors shares were down 1% at $57.05 at the time of writing, according to<a href="https://pro.benzinga.com/dashboard"> Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="550" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15132437/GM-1024x550.png" alt="" class="wp-image-651005" style="width:561px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15132437/GM-1024x550.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15132437/GM-300x161.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15132437/GM-768x412.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15132437/GM.png 1153w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/42015701/eyenovia-stock-sinks-as-pivotal-trial-fails-to-hit-primary-efficacy-goal-analyst-downgrades-due-to-limited-capital-and-near-term-upside-from-pipeline">Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline</a></li>
</ul>
Image via Shutterstock.

What's Going On With General Motors Today?

Guggenheim analyst Debjit Chattopadhyay maintains Centessa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTA#NASDAQ">CNTA</a>) with a Buy and raises the price target from $24 to $28.

CNTA

Guggenheim Maintains Buy on Centessa Pharmaceuticals, Raises Price Target to $28

Telsey Advisory Group analyst Dana Telsey maintains Capri Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>) with a Market Perform and lowers the price target from $26 to $23.

CPRI

Telsey Advisory Group Maintains Market Perform on Capri Holdings, Lowers Price Target to $23

Guggenheim analyst Michael Schmidt maintains Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) with a Buy and lowers the price target from $4 to $3.

ADAP

Guggenheim Maintains Buy on Adaptimmune Therapeutics, Lowers Price Target to $3

Western Midstream (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WES#NYSE">WES</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $39.5, a high estimate of $42.00, and a low estimate of $37.00. This current average reflects an increase of 0.43% from the previous average price target of $39.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1731697263_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Western Midstream by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shneur Gershuni</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$37.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Robert Kad</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$40.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Elvira Scotto</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$41.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Shneur Gershuni</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$39.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Robert Kad</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$42.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Elvira Scotto</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$38.00</td>
<td>$36.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Western Midstream. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Western Midstream compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Western Midstream's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Western Midstream's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WES/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Western Midstream analyst ratings.</a>
<h2>All You Need to Know About Western Midstream</h2>
Western Midstream Partners LP is a US-based company which own, operate, acquire and develop midstream energy assets. The company through its subsidiary is engaged in the business of gathering, processing, compressing, treating and transporting natural gas, condensate, NGLs and crude oil. It owns or has investments in assets located in the Rocky Mountains (Colorado, Utah, and Wyoming), the Mid-Continent (Kansas and Oklahoma), North-central Pennsylvania and Texas.
<h3>Western Midstream: Financial Performance Dissected</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Western Midstream's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 13.83% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Energy sector.
Net Margin: Western Midstream's net margin excels beyond industry benchmarks, reaching 31.9%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Western Midstream's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 8.64%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Western Midstream's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.24%, the company showcases efficient use of assets and strong financial health.
Debt Management: Western Midstream's debt-to-equity ratio surpasses industry norms, standing at 2.45. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Evaluating Western Midstream: Insights From 6 Financial Analysts

Applied Digital Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) stock is trading higher Friday as Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) gained exposure to the stock.
Nvidia&#8217;s <a target="_blank" href="https://www.benzinga.com//node/41990548" rel="noreferrer noopener">13F fling</a> shows it purchased 7.72 million Applied Digital shares worth $63.66 million as of September 30, 2024, which translates into close to a 3.6% stake in Applied Digital, which had 215.36 million outstanding shares as of October&nbsp;8, 2024,
Applied Digital, a U.S. company, delivers cutting-edge digital infrastructure tailored for high-performance computing and AI applications.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/24/11/42008569/salesforce-loses-ai-chief-amid-major-push-for-autonomous-agents" rel="noreferrer noopener">Salesforce Loses AI Chief Amid Major Push for Autonomous Agents</a>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15125158/newplot-9.png" alt="" class="wp-image-650883" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15125158/newplot-9.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15125158/newplot-9-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
Applied Digital <a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41260729/applied-digital-shares-dip-after-q1-results-details" rel="noreferrer noopener">reported a first-quarter</a> EPS loss of 15 cents, outperforming the analyst loss estimate of 29 cents. Revenue for the quarter reached $60.7 million, surpassing the expected $54.85 million.
The company attributed the revenue boost to recognizing income from its Cloud Services segment following the launch of the service at the end of the prior fiscal year.
Applied Digital had secured $160 million in September through a private placement involving institutional and accredited investors, including Nvidia.
Applied Digital planned to <a target="_blank" href="https://www.benzinga.com/news/24/09/40733450/applied-digital-corp-shares-are-trading-higher-today-what-you-need-to-know" rel="noreferrer noopener">allocate the proceeds</a> toward expanding its data centers and developing AI cloud infrastructure, strengthening its position in the AI and high-performance computing (HPC) markets.
The company is advancing a large-scale data center project in North Dakota while scaling up its cloud-computing operations.
Also, on November 4, Applied Digital <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41728245/applied-digital-corporation-announces-closing-of-450-million-of-convertible-notes-offering" rel="noreferrer noopener">completed raising $450 million</a> via an upsized private convertible notes offering to fund share repurchases of the company&#8217;s common stock.
The filing shows Nvidia retained its stake in Arm Holdings Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>), Nano-X Imaging Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNOX#NASDAQ">NNOX</a>), Recursion Pharmaceuticals, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), Serve Robotics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) and SoundHound AI, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>).
As of September 30, 2024, the U.S. chip designer held 1.96 million Arm shares worth $280.41 million, 0.06 million shares of Nano-X Imaging worth $0.36 million, 7.71 million Recursion Pharmaceuticals shares worth $50.78 million, 3.73 million Serve Robotics shares worth $29.63 million, and 1.73 million SoundHound AI shares worth $8.07 million.
Oppenheimer&#8217;s Rick Schafer reaffirmed his Outperform rating for Nvidia, raising the <a target="_blank" href="https://www.benzinga.com/24/11/42005107/nvidia-set-for-gains-from-ai-cloud-demand-blackwell-launch-and-data-center-expansion-analyst-notes" rel="noreferrer noopener">price target from $150 to $175</a>.
He maintains a bullish long-term outlook, emphasizing Nvidia&#8217;s leadership in AI hardware, robust margins, and strong data center ecosystem as key growth drivers.
Schafer expects Nvidia&#8217;s third-quarter results and January guidance to surpass estimates due to strong demand for AI products from cloud providers and enterprise clients.
He revised his projections upward, driven by high traction for Hopper AI accelerators and the initial ramp-up of Nvidia&#8217;s Blackwell chips in the fourth quarter.
Schafer forecasts Blackwell to generate several billion dollars in revenue in the January quarter despite supply constraints from CoWoS-L capacity.
Price Actions:&nbsp;At last check on Friday, APLD stock was up 7.73% at $7.39. NVDA stock is down 3.24%.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42011906/exxon-mobil-set-to-cut-400-texas-jobs-after-pioneer-deal" target="_blank" rel="noreferrer noopener">Exxon Mobil To Cut 400 Texas Jobs In Stages Through 2026</a></li>
</ul>

APLD

NNOX

NVDA

RXRX

SERV

SOUN

Nvidia Reveals 3.6% Stake In Applied Digital, Stock Soars

State Street (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STT#NYSE">STT</a>) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated State Street and provided 12-month price targets. The average target is $100.0, accompanied by a high estimate of $108.00 and a low estimate of $87.00. This upward trend is apparent, with the current average reflecting a 5.14% increase from the previous average price target of $95.11.
<img src="https://www.benzinga.com/files/images/story/2024/1731697247_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive State Street. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mike Mayo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$108.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$95.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Jason Goldberg</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$108.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Mike Mayo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$106.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Glenn Schorr</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$94.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Connor Lynagh</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$102.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Connor Lynagh</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$100.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Brian Bedell</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Hold</td>
<td>$87.00</td>
<td>$79.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to State Street. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of State Street compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of State Street's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of State Street's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/STT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on State Street analyst ratings.</a>
<h2>About State Street</h2>
State Street is a leading provider of financial services, including investment servicing, investment management, and investment research and trading. With approximately $42 trillion in assets under custody and administration and $4.1 trillion assets under management as of Dec. 31, 2023, State Street operates globally in more than 100 geographic markets and employs more than 46,000 worldwide.
<h3>State Street: A Financial Overview</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: State Street's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 18.1%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: State Street's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 21.46%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): State Street's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 3.01%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.21%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 1.34, State Street adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Key Takeaways From State Street Analyst Ratings

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Biote (NASDAQ:<a href="https://investorplace.com/stock-quotes/btmd-stock-quote/">BTMD</a>) just reported results for the second quarter of 2024.<ul><li>Biote reported earnings per share of -19 cents. This was below the analyst estimate for EPS of 9 cents.</li><li>The company reported revenue of $49.17 million.</li><li>This was 0.22% better than the analyst estimate for revenue of $49.06 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/btmd-stock-earnings-biote-for-q2-of-2024/">BTMD Stock Earnings: Biote Misses EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BTMD Stock Earnings: Biote Misses EPS, Beats Revenue for Q2 2024

BIOTE reports Q2 GAAP EPS of -$0.19

Roth MKM analyst George Kelly reiterated a Buy rating on biote (BTMD – Research Report) today and set a price target of $12.00. The company's share...

Roth MKM Keeps Their Buy Rating on biote (BTMD)

biote Corp. (BTMD) Q2 2024 Earnings Call Transcript

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on biote (BTMD – Research Report) and Ardent Health Par...

Analysts Are Bullish on These Healthcare Stocks: biote (BTMD), Ardent Health Partners, Inc. (ARDT)

BIOTE GAAP EPS of $0.33 beats by $0.26, revenue of $51.4M in-line

Biote Corp. ( ($BTMD) ) has released its Q3 earnings. Here is a breakdown of the information Biote Corp. presented to its investors. Biote Corp. is...

Biote Corp. Reports Steady Growth in Q3 2024

biote Corp. (BTMD) Q3 2024 Earnings Call Transcript

In a report released today, George Kelly from Roth MKM maintained a Buy rating on biote (BTMD – Research Report), with a price target of $11.00. Th...

biote (BTMD) Receives a Buy from Roth MKM

TD Cowen analyst Jonna Kim maintained a Buy rating on biote (BTMD – Research Report) yesterday and set a price target of $8.00. Jonna Kim's rating ...

Comments

Biote

Biote (BTMD) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO